4D Molecular Therapeutics Inc To Discuss Interim Data Update Call Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Gena Huidong Wang - Barclays Bank PLC. - Analyst : Thank you for taking my questions. I have a few. First for the two patients show improvement wondering is there any correlation with the protein expression. And also regarding the protein expression, I know you showed immunoassay and chemistry measurement having done Western blog on Mass Back, I think those will be much better quantification in terms of percentage of approaching improvement. Lastly, quickly regarding that accelerated -- potential accelerated approval path versus the Phase 3 and maybe give a little bit more thought regarding the baseline cutoff there, adding a 50 to 90 versus 40 to 80 FEV1 baseline?

Question: Tazeen Ahmad - Bank of America Corporation - Analyst : Okay, great. And a few for me as well. So the 1E15 that you've decided to move forward with, is that all nine patients are going to be those of that level ? Or do you have any opportunity to dose higher with some of those patients? And then by the time you reach the middle of next year when we expect to have this interim read, will any of the patients have reached 12 months and have had a biopsy. And then lastly, just based on the data you've collected so far, just wanted some more clarification about the path to accelerated approval, especially for the patients who don't have any other options currently. What is the FDA indicated if anything on the minimum threshold, is it number or a level of efficacy that would be needed to support such a path? Thanks.

Question: Jonathan Miller - Evercore ISI - Analyst : Hi, guys. Thanks for taking my question and congrats on all the data. I would also like to ask a question on the go-forward dose that you've picked and maybe coming from the other direction, given that it seems like even the very lowest dose that you've looked at delivers super physiological CFTR protein levels. I guess are you going with 1E15 just because you have the safety coverage there already? Or is there a clear expectation that dose is going to perform better than these lower doses that are still at super physiological CFTR?